Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS235 in overweight and obese subjects
NCT06714825Phase 1Completed
- Sponsor
- 35Pharma
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Fc Fusion Proteins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing HS235 with Placebo (2 arms). Primary endpoint: Adverse Events at 147 days. Started Nov 2024; status: completed.
02
Drugs
HS235
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06714825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714825.